Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?
Argenx Shares Drop After Q1 Miss, But Retail Traders Call Sub-$550 ‘An Absolute Steal’ Despite the Q1 miss, management reiterated confidence in its long-term “Vision 2030” strategy, highlighting strong Vyvgart uptake in gMG and CIDP and the recent U.S. approval of a self-injection option.
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble The company's drug treats two autoimmune conditions and recently launched with a prefilled synringe for at-home treatment.
Does ARGENX SE - ADR (NASDAQ:ARGX) meet the Minervini criteria? A fundamental and technical analysis of (
NASDAQ:ARGX ): Is ARGENX SE - ADR (
NASDAQ:ARGX ) suited for high growth investing?
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
